Opdivo Lung Cancer Study has Met its Target: DMC

January 12, 2015 1:38 PM

16 0

Pharmaceutical major Bristol-Myers Squibb Co has informed that a late-stage study that was evaluating Opdivo versus docetaxel in previously treated patients with advanced 'non-small cell' lung cancer has been stopped early. The independent Data Monitoring Committee (DMC) concluded that the study has met its endpoint.

The company, headquartered in New York, said the data demonstrated a superior overall survival in patients who have been receiving Opdivo as compared to the control arm.

Read more

To category page